Reported Earnings • May 20
First quarter 2026 earnings released: NT$0.40 loss per share (vs NT$0.46 loss in 1Q 2025) First quarter 2026 results: NT$0.40 loss per share. Revenue: NT$85.8m (down 22% from 1Q 2025). Net loss: NT$38.7m (loss widened 6.0% from 1Q 2025). Reported Earnings • Mar 20
Full year 2025 earnings released: NT$2.07 loss per share (vs NT$2.52 loss in FY 2024) Full year 2025 results: NT$2.07 loss per share. Revenue: NT$377.0m (down 1.1% from FY 2024). Net loss: NT$193.0m (loss widened 12% from FY 2024). Ankündigung • Mar 16
Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026 Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, Jun 12, 2026. Location: 15 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan New Risk • Dec 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$170m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$3.04b market cap, or US$97.2m). Reported Earnings • Nov 18
Third quarter 2025 earnings released: NT$0.43 loss per share (vs NT$0.43 loss in 3Q 2024) Third quarter 2025 results: NT$0.43 loss per share (further deteriorated from NT$0.43 loss in 3Q 2024). Revenue: NT$67.4m (down 36% from 3Q 2024). Net loss: NT$42.1m (loss widened 36% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Sep 03
Second quarter 2025 earnings released: NT$0.55 loss per share (vs NT$0.62 loss in 2Q 2024) Second quarter 2025 results: NT$0.55 loss per share. Revenue: NT$86.0m (down 4.0% from 2Q 2024). Net loss: NT$53.5m (loss widened 20% from 2Q 2024). Reported Earnings • May 16
First quarter 2025 earnings released: NT$0.46 loss per share (vs NT$0.62 loss in 1Q 2024) First quarter 2025 results: NT$0.46 loss per share. Revenue: NT$109.7m (up 76% from 1Q 2024). Net loss: NT$36.5m (loss widened 1.3% from 1Q 2024). Reported Earnings • Mar 19
Full year 2024 earnings released: NT$2.52 loss per share (vs NT$1.82 loss in FY 2023) Full year 2024 results: NT$2.52 loss per share (further deteriorated from NT$1.82 loss in FY 2023). Revenue: NT$381.3m (up 30% from FY 2023). Net loss: NT$172.8m (loss widened 66% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 14
Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025 Kuangli Bio-Tech Holdings Co., Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: 2 floor no,99, fu hsing n. rd., songshan district, taipei city Taiwan Ankündigung • Mar 04
Kuangli Bio-Tech Holdings Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025 Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025 Reported Earnings • Nov 19
Third quarter 2024 earnings released: NT$0.43 loss per share (vs NT$0.58 loss in 3Q 2023) Third quarter 2024 results: NT$0.43 loss per share (improved from NT$0.58 loss in 3Q 2023). Revenue: NT$105.2m (up 84% from 3Q 2023). Net loss: NT$30.9m (loss narrowed 6.3% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (NT$1.27b market cap, or US$39.2m). Ankündigung • Nov 05
Kuangli Bio-Tech Holdings Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024 Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q3, 2024 results on Nov 12, 2024 Reported Earnings • Aug 30
Second quarter 2024 earnings released: NT$0.62 loss per share (vs NT$0.15 loss in 2Q 2023) Second quarter 2024 results: NT$0.62 loss per share (further deteriorated from NT$0.15 loss in 2Q 2023). Revenue: NT$89.5m (down 14% from 2Q 2023). Net loss: NT$44.5m (loss widened 406% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. New Risk • Aug 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 29% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$38.5m). Ankündigung • Aug 17
Kuangli Bio-Tech Holdings Co., Ltd. to Report Q2, 2024 Results on Aug 26, 2024 Kuangli Bio-Tech Holdings Co., Ltd. announced that they will report Q2, 2024 results on Aug 26, 2024 New Risk • May 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (6.7% increase in shares outstanding). Market cap is less than US$100m (NT$787.8m market cap, or US$24.4m). New Risk • Apr 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (NT$732.7m market cap, or US$22.7m). New Risk • Dec 01
New major risk - Revenue and earnings growth Earnings have declined by 9.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$935.9m market cap, or US$29.8m). New Risk • Nov 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risks Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$947.3m market cap, or US$29.3m). New Risk • Sep 19
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$69m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$69m free cash flow). Minor Risk Market cap is less than US$100m (NT$1.02b market cap, or US$31.9m). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Shifang Qiu was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Apr 07
Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022 Kuangli Photoelectric Technology Co., Ltd., Annual General Meeting, Jun 21, 2022. Is New 90 Day High Low • Feb 22
New 90-day high: NT$34.10 The company is up 16% from its price of NT$29.30 on 24 November 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 23% over the same period. Is New 90 Day High Low • Jan 29
New 90-day high: NT$31.70 The company is up 19% from its price of NT$26.70 on 30 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 30% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: NT$26.80 The company is down 2.0% from its price of NT$27.35 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Electronic industry, which is also down 2.0% over the same period. 